Literature DB >> 24998884

Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process.

Laura A Adamson-Small1, Igor V Ignatovich2, Monica G Laemmerhirt3, Jacqueline A Hobbs4.   

Abstract

Parvovirus B19 (B19V) is a small non-enveloped DNA virus of the Parvoviridae family. It is an obligate human pathogen that preferentially replicates in erythroid progenitor cells. B19V is the causative agent of multiple erythroid-related diseases due to replication-induced cytotoxicity. Despite its strong erythroid tropism and related acute disease association, B19V has been determined to persist in many other non-erythroid tissues. This review summarizes and appraises what is known about concomitant B19V DNA persistence and non-acute viral gene expression in various, particularly non-erythroid, tissue types. The methods utilized for B19V detection are described, focusing on the discrepancies in outcomes among the employed assays. The studies where investigations focused on the impact of persistent B19V expression on cellular signaling pathways are also summarized. These studies demonstrate the expanse of the types of cells capable of in vivo B19V expression as well as the possible effect of persistent viral infection on the cellular microenvironment. Overall, these reports indicate that B19V commonly persists in a wide range of both erythroid and non-erythroid tissues, and that low-level viral gene expression can be detected in some persistently infected cells. B19V capsid RNA or proteins have been reported in bone marrow, colon, heart, liver, lymphoid, synovial, testicular, and thyroid tissues. In a sub-set of these cases, B19V capsid mRNA or proteins have been associated with increased inflammatory-related gene expression. The development of standard protocols to assay for B19V infection and expression in the context of non-erythroid, non-acute disease is warranted, and with further targeted studies, may begin to elucidate the impact of persistent B19V infection in vivo. These studies may determine the most conducive cellular environment for persistent gene expression and possible impact on disease pathogenesis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Erythroid; Erythrovirus; Inflammation; Parvovirus

Mesh:

Year:  2014        PMID: 24998884     DOI: 10.1016/j.virusres.2014.06.017

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  28 in total

1.  Parvovirus B19 integration into human CD36+ erythroid progenitor cells.

Authors:  Tyler Janovitz; Susan Wong; Neal S Young; Thiago Oliveira; Erik Falck-Pedersen
Journal:  Virology       Date:  2017-08-12       Impact factor: 3.616

2.  RNA Binding Protein RBM38 Regulates Expression of the 11-Kilodalton Protein of Parvovirus B19, Which Facilitates Viral DNA Replication.

Authors:  Safder S Ganaie; Aaron Yun Chen; Chun Huang; Peng Xu; Steve Kleiboeker; Aifang Du; Jianming Qiu
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 3.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  Evaluation of Molecular Test for the Discrimination of "Naked" DNA from Infectious Parvovirus B19 Particles in Serum and Bone Marrow Samples.

Authors:  Arthur Daniel Rocha Alves; Barbara Barbosa Langella; Mariana Magaldi de Souza Lima; Wagner Luís da Costa Nunes Pimentel Coelho; Rita de Cássia Nasser Cubel Garcia; Claudete Aparecida Araújo Cardoso; Renato Sergio Marchevsky; Marcelo Alves Pinto; Luciane Almeida Amado
Journal:  Viruses       Date:  2022-04-18       Impact factor: 5.818

5.  Human parvovirus B19 VP1u Protein as inflammatory mediators induces liver injury in naïve mice.

Authors:  Tsai-Ching Hsu; Chun-Ching Chiu; Shun-Chih Chang; Hsu-Chin Chan; Ya-Fang Shi; Tzy-Yen Chen; Bor-Show Tzang
Journal:  Virulence       Date:  2015-12-02       Impact factor: 5.882

6.  Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients.

Authors:  Heinz-Peter Schultheiss; Thomas Bock; Heiko Pietsch; Ganna Aleshcheva; Christian Baumeier; Friedrich Fruhwald; Felicitas Escher
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

7.  The Receptor-Binding Domain in the VP1u Region of Parvovirus B19.

Authors:  Remo Leisi; Chiarina Di Tommaso; Christoph Kempf; Carlos Ros
Journal:  Viruses       Date:  2016-02-24       Impact factor: 5.048

8.  Hepatic inflammation resulting from localized, subcutaneous expression of Parvovirus VP1u capsid protein: Importance and implication.

Authors:  Laura A Adamson-Small; Blanca Haydé Ruiz-Ordaz
Journal:  Virulence       Date:  2016-01-19       Impact factor: 5.882

9.  Phosphorylated STAT5 directly facilitates parvovirus B19 DNA replication in human erythroid progenitors through interaction with the MCM complex.

Authors:  Safder S Ganaie; Wei Zou; Peng Xu; Xuefeng Deng; Steve Kleiboeker; Jianming Qiu
Journal:  PLoS Pathog       Date:  2017-05-01       Impact factor: 6.823

10.  Cutavirus in Cutaneous Malignant Melanoma.

Authors:  Sarah Mollerup; Helena Fridholm; Lasse Vinner; Kristín Rós Kjartansdóttir; Jens Friis-Nielsen; Maria Asplund; Jose A R Herrera; Torben Steiniche; Tobias Mourier; Søren Brunak; Eske Willerslev; Jose M G Izarzugaza; Anders J Hansen; Lars P Nielsen
Journal:  Emerg Infect Dis       Date:  2017-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.